Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 294, Issue 4, 2008, Pages

  Phrommintikul, Arintaya ^a,b   Tran, Lavinia ^a   Kompa, Andrew ^a,c   Wang, Bing ^a   Adrahtas, Anastasia ^a   Cantwell, Danielle ^a   Kelly, Darren J ^c   Krum, Henry ^a,d  

^a MONASH UNIVERSITY   (Australia)

^b Faculty of Medicine Chiang Mai University   (Thailand)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ALFRED HOSPITAL   (Australia)

Author keywords

Diastolic function; Fibrosis; Hypertension; Hypertrophy; Myocardium; Pressure overload; Rho kinase

Indexed keywords

COLLAGEN; GSK 576371; RAMIPRIL; RHO KINASE; RHO KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; BLOOD FLOW VELOCITY; CARDIOVASCULAR EFFECT; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DRUG DOSE COMPARISON; ENZYME INHIBITION; FIBROSIS; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HYPERTENSION; MALE; MITRAL VALVE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANIMALS, NEWBORN; ANTIHYPERTENSIVE AGENTS; AORTA, ABDOMINAL; BODY WEIGHT; CARDIOMEGALY; CELL PROLIFERATION; CELL SIZE; CELLS, CULTURED; COLLAGEN; DIASTOLE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY; FIBROBLASTS; FIBROSIS; HEMODYNAMICS; HYPERTENSION; IMMUNOHISTOCHEMISTRY; LIGATION; MALE; MYOCARDIUM; MYOCYTES, CARDIAC; POLYMERASE CHAIN REACTION; PROTEIN KINASE INHIBITORS; RAMIPRIL; RATS; RATS, SPRAGUE-DAWLEY; RHO-ASSOCIATED KINASES; VENTRICULAR FUNCTION, LEFT;

EID: 41749089597     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01078.2007     Document Type: Article

References (43)

1. Antonello JM, Clark RL, Heyse JF. Applicaton of the Tukey trend test procedure to assess developmental and reproductive toxicity. Toxicol Sci 21: 52-58, 1993.
2. Aronow WS, Ahn C. Association of electrocardiographic left ventricular hypertrophy with the incidence of new congestive heart failure. J Am Geriatr Soc 46: 1280-1281, 1998.
3. Briganti EM, Shaw JE, Chadban SJ, Zimmet PZ, Welborn TA, McNeil JJ, Atkins RC. Untreated hypertension among Australian adults: the 1999-2000 Australian Diabetes, Obesity and Lifestyle Study (Aus-Diab). Med J Aust 179: 135-139, 2003.
4. Brilla CG, Maisch B, Weber KT. Myocardial collagen matrix remodelling in arterial hypertension. Eur Heart J 13, Suppl D: 24 -32, 1992.
5. Brilla CG, Reams GP, Maisch B, Weber KT. Renin-angiotensin system and myocardial fibrosis in hypertension: regulation of the myocardial collagen matrix. Eur Heart J 14, Suppl J: 57-61, 1993.
6. Connelly KA, Prior DL, Kelly DJ, Feneley MP, Krum H, Gilbert RE. Load-sensitive measures may overestimate global systolic function in the presence of left ventricular hypertrophy: a comparison with load-insensitive measures. Am J Physiol Heart Circ Physiol 290: H1699-H1705, 2006.
7. Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM, Manolio TA, Dries DL, Siscovick DS. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol 43: 2207-2215, 2004.
8. Fukui S, Fukumoto Y, Suzuki J, Saji K, Nawata J, tawara s Shinoazaki T, Kagaya Y, Shimokawa H. The important role fo Rho-kinase Pathway in the pathogenesis of diastolic heart failure in rats (abstract). J Card Fail 13: 008, 2007.
9. Ganau A, Devereux R, Roman M, Simone Gd Pickering T, Saba P, Vargiu P, Simongini I, Laragh J. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 19: 1550-1558, 1992.
10. Gardin JM, McClelland R, Kitzman D, Lima JA, Bommer W, Klopfenstein HS, Wong ND, Smith VE, Gottdiener J. M-mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the Cardiovascular Health Study). Am J Cardiol 87: 1051-1057, 2001.
11. Gerard PA. Diastolic heart failure: a common and lethal condition by any name (Abstract). New Engl J Med 355: 308, 2006.
12. Haider AW, Larson MG, Franklin SS, Levy D. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 138: 10-16, 2003.
13. Hattori T, Shimokawa H, Higashi M, Hiroki J, Mukai Y, Tsutsui H, Kaibuchi K, Takeshita A. Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation 109: 2234-2239, 2004.
14. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, Ichiki T, Takahashi S, Takeshita A. Long-term inhibition of Rhokinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res 93: 767-775, 2003.
15. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 43: 317-327, 2004.
16. Jalil J, Lavandero S, Chiong M, Paz Ocaranza M. Rho/Rho kinase signal transduction pathway in cardiovascular disease and cardiovascular remodeling. Rev Espan Cardiol 58: 951-961, 2005.
17. Kai H, Kuwahara F, Tokuda K, Imaizumi T. Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis. Hypertens Res 28: 483-490, 2005.
18. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 365: 217-223, 2005.
19. Kobayashi N, Horinaka S, Mita S, Nakano S, Honda T, Yoshida K, Kobayashi T, Matsuoka H. Critical role of Rho-kinase pathway for cardiac performance and remodeling in failing rat hearts. Cardiovasc Res 55: 757-767, 2002.
20. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 114: 345-352, 1991.
21. Kuwahara F, Kai H, Tokuda K, Takeya M, Takeshita A, Egashira K, Imaizumi T. Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension 43: 739-745, 2004.
22. Martin J, Denver R, Bailey M, Krum H. In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodelling. Clin Exp Pharmacol Physiol 32: 697-701, 2005.
23. Mita S, Kobayashi N, Yoshida K, Nakano S, Matsuoka H. Cardioprotective mechanisms of Rho-kinase inhibition associated with eNOS and oxidative stress-LOX-1 pathway in Dahl salt-sensitive hypertensive rats. J Hypertens 23: 87-96, 2005.
24. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 27: 1214-1218, 1996.
25. Mukai Y, Shimokawa H, Matoba T, Kandabashi T, Satoh S, Hiroki J, Kaibuchi K, Takeshita A. Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. Faseb J 15: 1062-1064, 2001.
26. Muller-Brunotte R, Edner M, Malmqvist K, Kahan T. Irbesartan and atenolol improve diastolic function in patients with hypertensive left ventricular hypertrophy. J Hypertens 23: 633-640, 2005.
27. Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 47: 320-332, 2005.
28. Pardo Mindan FJ, Panizo A. Alterations in the extracellular matrix of the myocardium in essential hypertension. Eur Heart J 14, Suppl J: 12-14, 1993.
29. Rikitake Y, Oyama N, Wang CY, Noma K, Satoh M, Kim HH, Liao JK. Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1+/- haploinsufficient mice. Circulation 112: 2959-2965, 2005.
30. Satoh S, Ueda Y, Koyanagi M, Kadokami T, Sugano M, Yoshikawa Y, Makino N. Chronic inhibition of Rho kinase blunts the process of left ventricular hypertrophy leading to cardiac contractile dysfunction in hypertension-induced heart failure. J Mol Cell Cardiol 35: 59-70, 2003.
31. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I, Silverman NH, Tajik AJ. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2: 358-367, 1989.
32. See F, Thomas W, Way K, Tzanidis A, Kompa A, Lewis D, Itescu S, Krum H. p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat. J Am Coll Cardiol 44: 1679-1689, 2004.
33. Shimokawa H, Takeshita A. Rho-Kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 25: 1767-1775, 2005.
34. Simpson P. Stimulation of hypertrophy of cultured neonatal rat heart cells through an alpha 1-adrenergic receptor and induction of beating through an alpha 1- and beta 1-adrenergic receptor interaction. Evidence for independent regulation of growth and beating. Circ Res 56: 884-894, 1985.
35. Thomas WG, Brandenburger Y, Autelitano DJ, Pham T, Qian H, Hannan RD. Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ Res 90: 135-142, 2002.
36. Torsoni AS, Fonseca PM, Crosara-Alberto DP, Franchini KG. Early activation of p160ROCK by pressure overload in rat heart. Am J Physiol Cell Physiol 284: C1411-C1419, 2003.
37. Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F, Kelly DJ, Gilbert RE, Krum H. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 93: 246-253, 2003.
38. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 33: 1948-1955, 1999.
39. Wang YX, da Cunha V, Martin-McNulty B, Vincelette J, Li W, Choy DF, Halks-Miller M, Mahmoudi M, Schroeder M, Johns A, Light DR, Dole WP. Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice. Eur J Pharmacol 512: 215-222, 2005.
40. Woodcock EA, Wang BH, Arthur JF, Lennard A, Matkovich SJ, Du XJ, Brown JH, Hannan RD. Inositol polyphosphate 1-phosphatase is a novel antihypertrophic factor. J Biol Chem 277: 22734-22742, 2002.
41. Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, Yoshida J, Miwa T, Sugawara M, Yamaguchi Y, Ookawara T, Suzuki K, Hori M. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res 55: 76-82, 2002.
42. Zhang YM, Bo J, Taffet GE, Chang J, Shi J, Reddy AK, Michael LH, Schneider MD, Entman ML, Schwartz RJ, Wei L. Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis. Faseb J 20: 916-925, 2006.
43. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation 105: 1503-1508, 2002.